Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Adrenal Hyperplasia, Congenital 2ACTH Syndrome, Ectopic 2Hypertension 1Cushing Syndrome 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Osilodrostat × 1 year × Clear all
NCT07247058 2026-03-05

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Johns Hopkins University

Phase 4 Recruiting
10 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Hypertension

NCT07104812 2026-02-11

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

Phase 2 Recruiting
15 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡